These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25311967)

  • 1. Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics.
    Guiu B; Schmitt A; Reinhardt S; Fohlen A; Pohl T; Wendremaire M; Denys A; Blümmel J; Boulin M
    J Vasc Interv Radiol; 2015 Feb; 26(2):262-70. PubMed ID: 25311967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment.
    Borde T; Laage Gaupp F; Geschwind JF; Savic LJ; Miszczuk M; Rexha I; Adam L; Walsh JJ; Huber S; Duncan JS; Peters DC; Sinusas A; Schlachter T; Gebauer B; Hyder F; Coman D; van Breugel JMM; Chapiro J
    J Vasc Interv Radiol; 2020 Oct; 31(10):1706-1716.e1. PubMed ID: 32684417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting beads loaded with antiangiogenic agents for chemoembolization: in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal model.
    Fuchs K; Bize PE; Dormond O; Denys A; Doelker E; Borchard G; Jordan O
    J Vasc Interv Radiol; 2014 Mar; 25(3):379-87, 387.e1-2. PubMed ID: 24468044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Deipolyi AR; Oklu R; Al-Ansari S; Zhu AX; Goyal L; Ganguli S
    J Vasc Interv Radiol; 2015 Apr; 26(4):516-22. PubMed ID: 25704226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.
    Boulin M; Schmitt A; Delhom E; Cercueil JP; Wendremaire M; Imbs DC; Fohlen A; Panaro F; Herrero A; Denys A; Guiu B
    Eur Radiol; 2016 Feb; 26(2):601-9. PubMed ID: 26060065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial.
    Boulin M; Hillon P; Cercueil JP; Bonnetain F; Dabakuyo S; Minello A; Jouve JL; Lepage C; Bardou M; Wendremaire M; Guerard P; Denys A; Grandvuillemin A; Chauffert B; Bedenne L; Guiu B
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1301-13. PubMed ID: 24738629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries.
    Lokken RP; Fidelman N; Kolli KP; Kerlan RK
    J Vasc Interv Radiol; 2016 Nov; 27(11):1698-1704. PubMed ID: 27397617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial.
    Guiu B; Chevallier P; Assenat E; Barbier E; Merle P; Bouvier A; Dumortier J; Nguyen-Khac E; Gugenheim J; Rode A; Oberti F; Valette PJ; Yzet T; Chevallier O; Barbare JC; Latournerie M; Boulin M
    Radiology; 2019 Jun; 291(3):801-808. PubMed ID: 31038408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma.
    Kucukay F; Badem S; Karan A; Ozdemir M; Okten RS; Ozbulbul NI; Kucukay MB; Unlu I; Bostanci EB; Akdogan M
    J Vasc Interv Radiol; 2015 Nov; 26(11):1622-9. PubMed ID: 26321015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An In Vitro Evaluation of Four Types of Drug-Eluting Embolics Loaded with Idarubicin.
    Guiu B; Hincapie G; Thompson L; Wu Y; Boulin M; Cassinotto C; Cruise GM
    J Vasc Interv Radiol; 2019 Aug; 30(8):1303-1309. PubMed ID: 31155500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis.
    Lee M; Chung JW; Lee KH; Won JY; Chun HJ; Lee HC; Kim JH; Lee IJ; Hur S; Kim HC; Kim YJ; Kim GM; Joo SM; Oh JS
    J Vasc Interv Radiol; 2017 Apr; 28(4):502-512. PubMed ID: 27856136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens.
    D'inca H; Piot O; Diebold MD; Piardi T; Marcus C; Burde F; Sommacale D; Manfait M; Thiéfin G
    J Vasc Interv Radiol; 2017 Jun; 28(6):804-810. PubMed ID: 28532743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Wu X; Chapiro J; Malhotra A; Kothary N
    J Vasc Interv Radiol; 2021 Jan; 32(1):2-12.e1. PubMed ID: 33160827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma.
    Nicolini A; Martinetti L; Crespi S; Maggioni M; Sangiovanni A
    J Vasc Interv Radiol; 2010 Mar; 21(3):327-32. PubMed ID: 20097098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization.
    Lewis AL; Gonzalez MV; Lloyd AW; Hall B; Tang Y; Willis SL; Leppard SW; Wolfenden LC; Palmer RR; Stratford PW
    J Vasc Interv Radiol; 2006 Feb; 17(2 Pt 1):335-42. PubMed ID: 16517780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Safety and Efficacy of 70-150 µm and 100-300 µm Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Tu J; Jia Z; Jiang G
    J Vasc Interv Radiol; 2015 Aug; 26(8):1251. PubMed ID: 26210251
    [No Abstract]   [Full Text] [Related]  

  • 19. Transarterial Chemoembolization in a Woodchuck Model of Hepatocellular Carcinoma.
    Pritchard WF; Woods DL; Esparza-Trujillo JA; Starost MF; Mauda-Havakuk M; Mikhail AS; Bakhutashvili I; Leonard S; Jones EC; Krishnasamy V; Karanian JW; Wood BJ
    J Vasc Interv Radiol; 2020 May; 31(5):812-819.e1. PubMed ID: 32107125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial.
    Guiu B; Jouve JL; Schmitt A; Minello A; Bonnetain F; Cassinotto C; Piron L; Cercueil JP; Loffroy R; Latournerie M; Wendremaire M; Lepage C; Boulin M
    J Hepatol; 2018 Jun; 68(6):1163-1171. PubMed ID: 29427728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.